Skip to main content

Table 2 Differences in demographic, and clinical findings on admission in patients ≥ 80 years hospitalized with COVID-19 during the first and successive waves

From: Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain)

 

Total

N (%)

( n  = 5953)

First wave

N (%)

( n  = 4545)

Successive waves

N (%)

( n  = 1408)

p value

Age, years, median (IQR),

85.6 (82.3–89.2)

85.5 (82.2–89.0)

86.1 (82.6–89.7)

 < 0.001

Age, years, median (IQR),

   

0.003

 80–84 years

2271 (38.1)

1772 (39.0)

499 (35.4)

 

 85–89 years

2106 (35.4)

1622 (35.7)

484 (34.4)

 

 90–94 years

1185 (19.9)

864 (19.0)

321 (22.8)

 

  ≥ 95 years

391 (6.6)

287 (6.3)

104 (7.4)

 

Sex, Male

3024 (50.8)

2331 (51.3)

693 (49.2)

0.175

Acquisition

 Community

4172 (70.2)

3170 (69.9)

1002 (70.2)

0.341

 Nosocomial

426 (7.2)

330 (7.3)

96 (7.3)

0.492

 Nursing Home

1036 (22.8)

1036 (22.8)

309 (22.0)

0.566

Degree of dependence

   

 < 0.001

 Independent or mild

3178 (56.2)

2516 (56.4)

662 (47.2)

 

 Moderate

1486 (54.3)

1076 (24.1)

410 (29.2)

 

 Severe

1201 (20.5)

871 (19.5)

330 (23.5)

 

Comorbidities

 Baseline CCI, median (IQR)

6 (5–7)

6 (5–7)

6 (5–7)

0.007

 Baseline CCI ≥ 6, n (%)

2445 (42.1)

1892 (42.9)

553 (39.8)

0.006

 Hypertension

4516 (76.0)

3412 (75.2)

1104 (78.4)

0.014

 Non-atherosclerotic cardiovascular diseasesa

1918 (32.3)

1464 (32.3)

454 (32.3)

0.993

 Atherosclerotic cardiovascular diseasesb

1750 (29.6)

1320 (29.2)

431 (30.7)

0.306

 Dementia

1671 (28.1)

1269 (28.0)

402 (28.8)

0.678

 Diabetes mellitus

1645 (27.7)

1204 (26.6)

441 (31.3)

 < 0.001

 Chronic pulmonary diseasec

1144 (19.3)

850 (18.8)

294(20.9)

0.079

 Obesityf

893 (16.8)

675 (16.7)

218 (17.3)

0.584

 Malignancyd

806 (13.6)

615 (13.6)

191 (13.6)

0.993

 Moderate-to-severe kidney diseasee

692 (11.7)

521 (11.5)

171 (12.1)

0.476

Symptoms

 Duration of symptoms in days, median (IQR)

5 (2–7)

5 (2–7)

4 (2–7)

0.029

 Fever

4158 (70.2)

3338 (73.9)

820 (58.3)

 < 0.001

 Dyspnea

3621 (61.1)

2757 (61.0)

864 (61.4)

0.791

 Cough

3537 (59.6)

2791 (61.7)

746 (53.1)

 < 0.001

 Asthenia

2326 (39.6)

1696 (38.0)

630 (44.7)

 < 0.001

 Confusion

1644 (27.8)

1265 (28.1)

379 (27.0)

0.428

 Anorexia

1317 (22.5)

963 (21.6)

354 (25.1)

0.006

 Diarrhea

975 (16.5)

732 (16.3)

243 (17.3)

0.396

 Arthralgia-myalgias

983 (16.7)

774 (17.3)

209 (14.9)

0.032

 Vomiting

379 (6.4)

287 (6.4)

92 (6.5)

0.855

 Abdominal pain

320 (5.4)

255 (5.7)

65 (4.6)

0.118

 Odynophagia

330 (5.6)

272 (6.1)

58 (4.1)

0.005

 Headache

310 (5.3)

238 (5.3)

72 (5.1)

0.747

 Ageusia

183 (3.1)

145 (3.3)

38 (2.7)

0.275

 Anosmia

158 (2.7)

127 (2.9)

31 (2.2)

0.173

Physical examination

 Oxygen saturation ≤ 94%

3236 (51.4)

2334 (52.7)

902 (48.3)

0.001

 Temperature ≥ 37.8 ºC

1025 (16.7)

830 (19.4)

195 (10.6)

 < 0.001

 Hypotension

467 (7.5)

334 (7.6)

138 (7.1)

0.471

 Tachycardia

1203 (19.2)

881 (20.0)

322 (17.2)

0.009

 Tachypnea

2314 (39.6)

1810 (40.8)

504 (36.0)

0.001

 Pulmonary rhonchi

1087 (17.6)

847 (19.1)

240 (17.7)

0.218

 qSOFA index ≥ 2

1076 (16.7)

798 (17.6)

278 (14.6)

0.004

  1. CCI Charlson Comorbidity Index, IQR Interquartile range, N (%) Number of cases (percentage), qSOFA Quick sequential organ failure assessment
  2. aNon-atherosclerotic heart disease includes atrial fibrillation and/or heart failure. bAtherosclerotic cardiovascular disease includes coronary, cerebrovascular, and/or peripheral vascular disease. cChronic pulmonary disease includes chronic obstructive pulmonary diseases and/or asthma. dMalignancy includes solid tumors or hematological neoplasia. eKidney disease is defined as an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2 according to the CKD-EPI equation. fObesity is defined as a body mass index > 30 kg/ m2
  3. Statistically significant differences are indicated in bold